Video
β And nearly half of responders to enfortumab vedotin plus pembrolizumab remained in remission
Latest in Video
Our panel of experts discuss when might be the right time to reduce therapy
Faranak Kamangar on how the AI tool can be used in practice to make life easier for physicians
Our panel of experts discuss how they monitor patients on biologics and JAK inhibitors
Faranak Kamangar on how the AI tool can be used in practice to make life easier for physicians
Our panel of experts discuss how they monitor patients on biologics and JAK inhibitors
More in Video
Peter Lio, MD, says he can't wait to have more flexibility for his pediatric patients
Steven Feldman, MD, PhD, highlights the importance of improving quality of life
Our panel of experts discuss the appropriate time to introduce systemic therapy or switch agents
Our understanding of eczema's potential comorbidities will likely expand, says Lakshi Aldredge
We've got great treatments, says Steven Feldman, the key is getting patients to use them
Our panel of experts discuss the "explosion" in new systemic and topical agents
James Del Rosso, DO, says to keep an open mind when determining the best option for patients
Will be good news for patients when drug is approved, says Emma Guttman-Yassky, MD, PhD
Peter Lio, MD, discusses how he approaches that decision-making discussion
Roy Herbst, MD, PhD, leads a discussion on ADCs targeting TROP2, HER2, and HER3
Roy Herbst, MD, PhD, leads a discussion on current and emerging treatments available
Roy Herbst, MD, PhD, leads a discussion on the newest targeted and immunotherapies
Roy Herbst, MD, PhD, leads a discussion on new data coming down the pike
Results may lead to an alternative to JAK inhibitors
